NCT07667400

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-07-30Est. Completion: 2036-10-01

Enrollment target: 120 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

Michele L Reed, R.N.michele.reed@nih.gov (240) 760-6121

Charalampos Floudas, M.D.charalampos.floudas@nih.gov (240) 474-1575

Other microbiome trials you might be interested in

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerPhase 2SUSPENDED

Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuxima…

Birmingham, United StatesCompleted Jan 1, 2027

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.